Expression of fibrinolytic genes in tissues from human atherosclerotic aneurysms and from obese mice

Annals of the New York Academy of Sciences

Volumn 811, Issue , 1997, Pages 350-360

  Samad, Fahumiya ^a   Schneiderman, Jacob ^b,c   Loskutoff, David ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ABDOMINAL AORTA ANEURYSM; AORTA WALL; ATHEROSCLEROSIS; CONFERENCE PAPER; FIBRINOLYSIS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY;

EID: 0030743171     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1997.tb52014.x     Document Type: Conference Paper

References (68)

1. ASTRUP, T. 1958. The hemostatic balance. Thromb. Diath. Haem. 2: 347.
2. SPRENGERS, E. D. & C. KLUFT. 1987. Plasminogen activator inhibitors. Blood 69: 381-387.
3. VASSALLI, J. D., A. SAPPINO & D. BELIN. 1991. The plasminogen activator/plasmin system. J. Clin. Invest. 88: 1067-1072.
4. VAN MEIJER, M. & H. PANNEKOEK. 1995. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: An update. Fibrinolysis 9: 263-276.
5. BACHARACH, E., A. ITIN & E. KESHET. 1993. In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc. Natl. Acad. Sci. USA 89: 10686-10690.
6. STRICKLAND, S., E. REICH & M. I. SHERMAN. 1976. Plasminogen activator in early embryogenesis: enzyme production by trophoblast and parietal endoderm. Cell 9: 231-240.
7. LALA, P. K. & C. H. GRAHAM. 1990. Mechanisms of trophoblast invasiveness and their control: The role of proteases and protease inhibitors. Cancer Metastasis Rev. 9: 369-379.
8. 2-antiplasmin. Endocrinol. 124: 415-421.
9. OHLSSON, M., X. R. PENG, Y. X. LIU, C. JIA, A. J. W. HSUEH & T. NY. 1991. Hormone regulation of tissue-type plasminogen activator gene expression and plasminogen activator-mediated proteolysis. Semin. Thromb. Hemost. 17: 286-290.
10. HART, D. A. & A. REHEMTULLA. 1988. Plasminogen activators and their inhibitors: Regulators of extracellular proteolysis and cell function. Comp. Biochem. Physiol. 90B: 691-708.
11. BLASI, F. & P. VERDE. 1990. Urokinase-dependent cell surface proteolysis and cancer. Semin. Cancer Biol. 1: 117-126.
12. LIOTTA, L. A., P. S. STEEG & W. G. STETLER-STEVENSON. 1991. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336.
13. CARMELIET, P. & D. COLLEN. 1995. Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis: Evaluation in transgenic animals. Trends Cardiovasc. Med. 5: 117-122.
14. COLLEN, D. & H. R. LIJNEN. 1992. Fibrin-specific fibrinolysis. Ann. NY. Acad. Sci. 667: 259-271.
15. LOSKUTOFF, D. J. 1991. Regulation of PAI-1 gene expression. Fibrinolysis 5: 197-206.
16. DAWSON, S. & A. HENNEY. 1992. The status of PAI-1 as a risk factor for arterial and thrombotic disease: A review. Atherosclerosis 95: 105-117.
17. MUNRO, J. M. & R. S. COTRAN. 1988. The pathogenesis of atherosclerosis: Atherogenesis and inflammation. Lab. Invest. 58: 249-260.
18. ROSS, R. 1993. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801-809.
19. KOCH, A. E., K. HAINES, R. J. RIZZO, J. A. RADOSEVICH, R. M. POPE, P. G. ROBINSON & W. H. PEARCE. 1990. Human abdominal aortic aneurysms: Immunophenotypic analysis suggesting an immune-mediated response. Am. J. Pathol. 137: 1199-1213.
20. FEARNS, C., F. SAMAD & D. J. LOSKUTOFF. 1995. Synthesis and localization of PAI-1 in the vessel wall. In Advances in Vascular Biology. Gordon and Breach Publishers. Camberwell, Victoria, Australia.
21. POWELL, J. T. & R. M. GREENHALGH. 1989. Cellular, enzymatic and genetic factors in the pathogenesis of abdominal aortic aneurysms. J. Vasc. Surg. 9: 297-304.
22. BUSUTTIL, R. W., A. M. ABOU-ZAMZAM & H. I. MACHLEDER. 1980. Collagenase activity of the human aorta. Arch. Surg. 115: 1373-1378.
23. ZARINS, C. K., A. RUNYON-HASS, M. A. ZATINA, C. T. LU & S. GLAGOV. 1986. Increased collagenase activity in early aneurysmal dilatation. J. Vasc. Surg. 3: 238-248.
24. MCMILLAN, W. D., B. K. PATTERSON, R. R. KEEN, V. P. SHIVELY, M. CIPOLLONE & W. H. PEARCE. 1995. In situ localization and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta. Arterioscler. Thromb. Vasc. Biol. 15: 1139-1144.
25. ANIDJAR, S., J. L. SALZMANN, D. GENTRIC, P. LAGNEAU, J. P. CAMILLERI & J. B. MICHEL. 1990. Elastase-induced experimental aneurysms in rats. Circulation 82: 973-981.
26. ANIDJAR, S., P. B. DOBRIN, M. EICHORST, G. P. GRAHAM & G. CHEJFEC. 1992. Correlation of inflammatory infiltrate with the enlargement of experimental aortic aneurysms. J. Vasc. Surg. 16: 139-147.
27. THOMPSON, R. W., D. R. HOLMES, R. A. MERTENS, S. LIAO, M. D. BOTNEY, R. P. MECHAM, H. G. WELGUS & W. C. PARKS. 1995. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms: An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J. Clin. Invest. 96: 318-326.
28. LIOTTA, L. A., N. RAO & U. M. WEWER. 1986. Biochemical interactions of tumor cells with basement membrane. Annu. Rev. Biochem. 55: 1037-1057.
29. MURPHY, G., S. ATKINSON, R. WARD, J. GAVRILOVIC & J. J. REYNOLDS. 1992. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann. N.Y. Acad. Sci. 667: 1-12.
30. DECLERCK, P. J., M. DE MOL, M. C. ALESSI, S. BAUDNER, E. P. PAQUES, K. T. PREISSNER, G. M. BERHAUS & D. COLLEN. 1988. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J. Biol. Chem. 30: 15454-15461.
31. MIMURO, J. & D. J. LOSKUTOFF. 1989. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix: Evidence that the protein is vitronectin. J. Biol. Chem. 264: 936-939.
32. NICULESCU, F., H. G. RUS, D. PORUTIU, V. GHIURCA & R. VLAICU. 1989. Immunoelectron-microscopic localization of S-protein/vitronectin in human atherosclerotic wall. Atherosclerosis 78: 197-203.
33. GUETTIER, C., N. HINGLAIS, P. BRUNEVAL, M. KAZATCHKINE, J. BARIETY & J. CAMILLERI. 1989. Immunohistochemical localization of S protein/vitronectin in human atherosclerotic versus arteriosclerotic arteries. Virchows Archiv. A. Pathol. Anat. 414: 309-313.
34. ASTRUP, T. & S. COCCHERI. 1962. Thromboplastic and fibrinolytic activity of the arteriosclerotic aorta. Nature 193: 182-183.
35. REILLY, J. M., A. S. GREGORIO & C. L. LUCORE. 1994. Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease. J. Vasc. Surg. 19: 865-872.
36. TROMHOLT, N., S. J. JORGENSEN, B. HESSE & M. S. HANSEN. 1993. In vivo demonstration of focal fibrinolytic activity in abdominal aortic aneurysms. Eur. J. Vasc. Surg. 7: 675-679.
37. JEAN-CLAUDE, J., K. M. NEWMAN, H. LI, A. K. GREGORY & M. D. TILSON. 1994. Possible key role for plasmin in the pathogenesis of abdominal aortic aneurysms. Surgery 116: 472-478.
38. SCHNEIDERMAN, J., G. M. BORDIN, I. ENGELBERG, R. ADAR, D. SEIFFERT, T. THINNES, E. F. BERNSTEIN, R. B. DILLEY & D. J. LOSKUTOFF. 1995. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall: A possible mechanism for aneurysm expansion. J. Clin. Invest. 96: 639-645.
39. HOLMES, D. R., S. LIAO, W. C. PARKS & R. W. THOMPSON. 1995. Medial neovascularization in abdominal aortic aneurysms: A histopathologic marker of aneurysmal degeneration with pathophysiologic implications. J. Vasc. Surg. 21: 761-772.
40. GOWN, A. M., T. TSUKADA & R. ROSS. 1986. Human atherosclerosis. II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am. J. Pathol. 125: 191-207.
41. BARGER, A. C., R. BEEUWKES, L. L. LAINEY & K. J. SILVERMAN. 1984. Hypothesis: Vasa vasorum and neovascularization of human coronary arteries. N. Engl. J. Med. 310: 175-177.
42. KAMAT, B. R., S. J. GALLI, A. C. BARGER, L. L. LAINEY & K. J. SILVERMAN. 1987. Neovascularization and coronary atherosclerotic plaque: Cinematographic localization and quantitative histologic analysis. Hum. Pathol. 18: 1036-1042.
43. LARSSON, B. 1991. Obesity, fat distribution and cardiovascular disease. Int. J. Obesity 15: 53-57.
44. BJÖRNTORP, P. 1992. Abdominal fat distribution and disease: An overview of epidemiological data. Ann. Med. 24: 15-18.
45. DEFRONZO, R. A. & E. FERRANNINI. 1991. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194.
46. MCGILL, J. B., D. J. SCHNEIDER, C. L. ARFKEN, C. L. LUCORE & B. E. SOBEL. 1994. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43: 104-109.
47. POTTER VAN LOON, B. J., C. KLUFT, J. K. RADDER, M. A. BLANKENSTEIN & A. E. MEINDERS. 1993. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42: 945-949.
48. LEGNANI, C., M. MACCAFERRI, P. TONINI, A. CASSIO, E. CACCIARI & S. COCCHERI. 1988. Reduced fibrinolytic response in obese children: Association with high baseline activity of the fast acting plasminogen activator inhibitor (PAI-1). Fibrinolysis 2: 211-214.
49. VAGUE, P., I. JUHAN-VAGUE, V. CHABERT, M. C. ALESSI & C. ATLAN. 1989. Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism 38: 913-915.
50. TAKADA, Y., T. URANO, I. WATANABE, A. TAMINATO, T. YOSHIMI & A. TAKADA. 1993. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Thromb. Res. 71: 405-115.
51. JUHAN-VAGUE, I., B. MOERMAN, F. DE COCK, M. F. AILLAUD & D. COLLEN. 1984. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb. Res. 33: 523-530.
52. SUNDELL, I. B., T. K. NILSSON, G. HALLMANS, G. HELLSTEN & G. H. DAHLEN. 1989. Interrelationship between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a North Swedish population. Atherosclerosis 80: 9-16.
53. PRIMROSE, J. N., J. A. DAVIES, C. R. M. PRENTICE, R. HUGHES & D. JOHNSTON. 1992. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb. Haemost. 68: 396-399.
54. SAWDEY, M. S. & D. J. LOSKUTOFF. 1991. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo: Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J. Clin. Invest. 88: 1346-1353.
55. ASPLUND-CARLSON, A., A. HAMSTEN, B. WIMAN & L. A. CARLSON. 1993. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: Studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 36: 817-825.
56. JUHAN-VAGUE, I., C. ROUL, M. C. ALESSI, J. P. ARDISSONE, M. HEIM & P. VAGUE. 1989. Increased plasminogen activator inhibitor activity in non-insulin-dependent diabetic patients: Relationship with plasma insulin. Thromb. Haemostas. 61: 370-373.
57. VAGUE, P., I. JUHAN-VAGUE, M. F. AILLAUD, C. BADIER, R. VIARD, M. C. ALESSI & D. COLLEN. 1986. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 35: 250-253.
58. MYKKÄNEN, L., T. RÖNNEMAA, J. MARNIEMI, S. M. HAFFNER, R. BERGMAN & M. LAAKSO. 1994. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler. Thromb. 14: 1264-1271.
59. JAIN, S. K., D. K. NAGI, B. M. SLAVIN, P. J. LUMB & J. S. YUDKIN. 1993. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabetic Med. 10: 27-32.
60. ALESSI, M. C., I. JUHAN-VAGUE, T. KOOISTRA, P. J. DECLERCK & D. COLLEN. 1988. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb. Haemost. 60: 491-494.
61. ALESSI, M. C., F. ANFOSSO, M. HENRY, F. PEIRETTI, G. NALBONE & I. JUHAN-VAGUE. 1995. Up-regulation of PAI-1 synthesis by insulin and proinsulin in HEP G2 cells but not in endothelial cells. Fibrinolysis 9: 237-242.
62. SCHNEIDER, D. J. & B. E. SOBEL. 1991. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: Implications for vascular disease in hyperinsulinemic states. Proc. Natl. Acad. Sci. USA 88: 9959-9963.
63. HOTAMISLIGIL, G. S., N. S. SHARGILL & B. M. SPIEGELMAN. 1993. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 259: 87-91.
64. HOTAMISLIGIL, G. S., P. ARNER, J. F. CARO, R. L. ATKINSON & B. M. SPIEGELMAN. 1995. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95: 2409-2415.
65. KOOISTRA, T. 1990. The use of cultured human endothelial cells and hepatocytes as an in vitro model system to study modulation of endogenous fibrinolysis. Fibrinolysis 4: 33-39.
66. VAN HINSBERGH, V. W., T. KOOISTRA, E. A. VAN DEN BERG, H. M. PRINCEN, W. FIERS & J. J. EMEIS. 1988. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72: 1467-1473.
67. SAMAD, F., K. YAMAMOTO & D. J. LOSKUTOFF. 1996. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: Induction by tumor necrosis factor-α and lipopolysaccharide. J. Clin. Invest. 97: 37-46.
68. SAMAD, F. & D. J. LOSKUTOFF. 1996. Tissue distribution and insulin regulation of plasminogen activator inhibitor-1 in obese mice. Molec. Med 2: 568-582.